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To the Editor:
KRAS mutations are among the most common oncogenic
events in human carcinomas of endodermal origin, whose
presence predicts for resistance to several target therapies
[1]. Conversely, little is known regarding the role and/or
clinical impact of KRAS mutations in the setting of the
hematological malignancies, including chronic lymphocytic
leukemia (CLL), and only in recent years extensive
sequencing data have highlighted the recurrent mutations of
genes affecting the Ras–MAPK pathway in CLL [2, 3].
These mutations, by leading to a constitutive activation of
MAPK signaling pathway, have emerged as relevant in
driving impaired clinical responses to lenalidomide and
chlorambucil, and acquired resistance to ﬂudarabine as well
as to PI3K and BCL2 inhibitors [4–6]. In this context, some
studies pinpointed a higher frequency of mutations in
members of the Ras–MAPK pathway in CLL cases with
speciﬁc clinico-biological features [6, 7], including the
presence of trisomy 12, a cytogenetic aberration associated
with a unique pathophysiology among CLL [8, 9], and/or an
unmutated (UM) conﬁguration of IGHV genes, although a
dedicated and comprehensive analysis of these aspects is
still missing.
This study, approved by the IRB of the Aviano Centro di
Riferimento Oncologico (Approvals n. IRB-05-2010 and n.
IRB-05-2015), included 534 primary CLL from treatment-
naive patients. The cohort was purposely enriched in tris-
omy 12 CLL by including 110 cases from the Mayo Clinic,
Rochester, MN [8] to better evaluate the incidence of
mutations of the Ras–MAPK pathway in these subsets.
Overall, out of 534 cases, trisomy 12 CLL accounted for
300 cases (190 with trisomy 12 as the sole abnormality
[trisomy 12-only], and 110 with trisomy 12 plus another
abnormality on FISH [trisomy 12-plus]), 332 cases had UM
IGHV genes, and 214 cases had NOTCH1 aberrations
(details in Table S1). CLL patients were diagnosed and
treated according to the current iwCLL 2018 guidelines
[10], and all samples were collected at diagnosis from
treatment-naive patients. In 442/534 cases (clinical cohort),
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treatment-free survival (TFS) data were available along with
a comprehensive clinical and biological characterization
(Table S1 and Supplemental Methods). This cohort showed
the expected clinical behavior according to both the strati-
ﬁcation of the established cytogenetic categories and to the
canonical prognosticators by univariable and multivariable
analyses (Supplemental Figure S1 and Table S2). Mutation
testing for KRAS, NRAS, BRAF, TP53, NOTCH1, BIRC3,
and SF3B1 was performed on DNA from CD19+ enriched
CLL samples by Next Generation Sequencing (NGS) assays
with at least 1000 × coverage and 1% sensitivity (details in
Supplemental Methods). Groups were compared by chi-
square test; TFS was computed from diagnosis to treatment
and analyzed by log-rank test and Cox regression analysis
with a stepwise procedure using MedCalc Statistical Soft-
ware version 16.8.4 (MedCalc Software bvba, Ostend,
Belgium; https://www.medcalc.org; 2016).
The mutation analysis of the Ras–MAPK pathway was
focused on the KRAS, NRAS, and BRAF genes, previously
reported as the most frequently mutated genes among the
members of the pathway [2]. We found 91 missense point
mutations in 64 CLL cases, with a prevalence of KRAS
(44 mutations in 38 [7.1%] patients), followed by BRAF
(32 mutations in 24 [4.5%] patients) and NRAS (15 muta-
tions in 13 [2.4%] patients). Nearly all mutations were
previously associated with the gain-of-function phenotype
and increased RAS/ERK downstream signaling (Fig. 1a and
Table S3) [1]. In particular, among the most frequent KRAS/
NRAS mutations, almost half of the mutations (27/59, 45%),
overall affecting 23/49 (47%) patients, involved the G12/
G13 codons, in keeping with what was observed in colon
and lung cancers (Table S3) [1]. The co-occurrence of 2
mutated genes was observed in 11 cases (KRAS and BRAF
in 8/11 cases, KRAS and NRAS in 2/11 cases, NRAS and
BRAF in 1/11 cases), whereas mutations affecting all three
genes were not found in our cohort. The mutations were
mainly subclonal (mean Variant Allele Fraction, VAF,
12.3%, range 1.3–61.6%) with one-third of mutations (33/
91) above 10% VAF. The presence of multiple mutations
affecting the same gene occurred in 14 cases, including 5
cases that presented mutations in the same or adjacent
codons (i.e., one case with both K601N and K601E BRAF
mutations, one case with V600E and K601E BRAF muta-
tions, and three cases with two simultaneous KRAS muta-
tions at the G12 and G13 codons) suggesting that multiple
genetic hits are positively selected in different subclones
within the same leukemia specimen.
A strong association between KRAS/NRAS/BRAF muta-
tions and the presence of an UM IGHV gene status and
trisomy 12 was observed (Fig. 1b and Table S4). Overall,
87.3% of KRAS/NRAS/BRAF mutated cases had UM IGHV
(p < 0.0001) and 79.7% were trisomy 12 CLL (p < 0.0001).
Concordantly, the highest KRAS/NRAS/BRAF mutation
frequency was found in CLL patients with concomitant UM
IGHV and trisomy 12-only (38/133, 28.6%). This group
was characterized by 25 KRAS (18.8%), 8 NRAS (6%) and
11 BRAF (8.3%) mutated cases. Of note, the UM IGHV/
trisomy 12-only group was characterized by a higher fre-
quency of KRAS/NRAS/BRAF mutations also when com-
pared to the UM IGHV/trisomy 12-plus group (8/49,
16.3%). Finally, the lowest frequency of KRAS/NRAS/
BRAF mutations was observed in the context of CLL
patients with M IGHV (8/186, 4.3%) and del13q as the sole
chromosomal aberration (2/94, 2.1% in the whole cohort,
and 2/53, 3.8% in the context of UM IGHV cases).
We then correlated the presence of KRAS/NRAS/BRAF
mutations to other biological features (Table S4). When
considering the whole CLL cohort, the only variables
associated with a higher frequency of KRAS/NRAS/BRAF
mutations were the absence of BIRC3 mutations (p= 0.02)
and the positive expression (≥30%) of CD49d (p= 0.04).
On the other hand, if circumscribing the analysis to UM
IGHV/trisomy 12 CLL, CD49d positive expression lost its
association with KRAS/NRAS/BRAF mutations, as expected
due to the almost universal CD49d expression in trisomy
12 CLL patients [9]. Conversely, we observed a higher
frequency of KRAS/NRAS/BRAF mutations in NOTCH1
wild type cases (29/92, 31.5%) and BIRC3 wild type cases
(41/132, 31.1%) compared to their mutated counterparts
(NOTCH1 mutated: 17/90, 18.9%; BIRC3 mutated: 4/30,
13.3%; p= 0.05 in both cases), pointing to a mutual
exclusivity of these mutations in the pathogenesis of the
disease. No other signiﬁcant associations with other known
prognostic variables such as presence of TP53 mutations/
disruption, SF3B1 mutations, ZAP-70 and CD38 expres-
sion, Rai staging, age at diagnosis, and gender were
observed either in the whole cohort or in the UM IGHV/
trisomy 12 cohort (Table S4).
We ﬁnally evaluated the prognostic relevance of
KRAS, NRAS, and BRAF mutations as predictors of TFS.
In the context of the clinical cohort, the presence of either
KRAS or NRAS mutations or the concomitant presence of
KRAS/NRAS mutations were associated with shorter TFS
(p= 0.07, p= 0.05, and p= 0.02, respectively) (Table 1,
Fig. 1c). Conversely, BRAF mutations were not asso-
ciated with TFS, pointing to a secondary role of BRAF in
the Ras–MAPK pathway in CLL, in line with studies
indicating the lack of therapeutic effects of BRAF inhi-
bition in CLL [11]. In a multivariable model that included
the main known CLL prognosticators, the presence of
KRAS/NRAS mutations retained its independent prog-
nostic power as predictor for shorter TFS (p= 0.03,
Table 1). Moreover, circumscribing the analysis to the
CLL subgroup with the highest incidence of these
mutations (i.e., UM IGHV/trisomy 12-only/NOTCH1-
wt), both KRAS mutations alone (p= 0.005) and KRAS/
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Fig. 1 Type, incidence and prognostic impact of KRAS, NRAS and
BRAF mutations. a Lollipop plots of mutations found in KRAS, NRAS,
and BRAF genes. Sites and frequency of missense point mutations, and
schematic presentation of the protein structure and functional domains
are shown (MutationMapper, cBioPortal Version 1.14.0, Gao et al.
Sci. Signal. 2013 and Cerami et al. Cancer Discov. 2012). Gray boxes
indicate amino acids (aa) regions corresponding to the sequenced
amplicons. RBD, Ras-binding domain; C1_1, phorbol esters/dia-
cylglycerol binding domain (C1 domain); Pkinase_Tyr, protein
tyrosine kinase domain. b Co-mutation plot of 534 CLL analyzed for
KRAS, NRAS, BRAF mutations. Incidence of trisomy 12, KRAS, NRAS,
and BRAF missense mutations, NOTCH1 aberrations and IGHV status
are shown. c Kaplan–Meier curves of treatment-free survival (TFS) of
442 CLL patients stratiﬁed by the presence of KRAS and/or NRAS
mutations. d Kaplan–Meier curves of TFS of 61 CLL patients in the
IGHV unmutated/trisomy 12-only/NOTCH1-wt group stratiﬁed by the
presence of KRAS mutations
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NRAS mutations (p= 0.05) were associated with shorter
TFS (Fig. 1d and Table S5), and the presence of KRAS
mutations retained its prognostic value in a multivariable
analysis that included all the variables with an impact in
univariable analysis (p= 0.01, Table S5). The subclonal
or clonal pattern of KRAS/NRAS mutations had similar
negative impact in our series (not shown), as previously
observed for other gene mutations in CLL [12], and in
keeping with the known capability of KRAS mutated
tumor cells to enhance the overall tumor cell ﬁtness by
inﬂuencing the non-mutated neoplastic component [13].
In the present study, we demonstrated that KRAS,
NRAS, and BRAF mutations were almost exclusively
found in UM IGHV/trisomy 12 CLL and were almost
mutually exclusive with NOTCH1 and BIRC3 mutations.
The type of genomic structural variants, especially tris-
omy 12 and del13q, strongly inﬂuenced KRAS/NRAS/
BRAF mutation incidence, that turned out to be at the
highest level in cases bearing trisomy 12 as the sole
genomic aberration, intermediate in cases in which tris-
omy 12 was associated with other genetic aberrations,
mainly del13q, and at the lowest level in cases bearing
del13q as the sole FISH detectable genetic aberration.
This peculiar distribution of KRAS/NRAS/BRAF mutation
incidence is in keeping with a CLL pathogenetic model in
which the two main founder genetic lesions (i.e., trisomy
12 and del13q) identify CLL subgroups following dif-
ferent patho-biological pathways. In particular, the pre-
sence of del13q, given its link to the miR15/miR16-
BCL2 axis, characterizes a CLL subset especially orien-
ted toward the ampliﬁcation of anti-apoptotic signals
[14]. On the other hand, in trisomy 12 CLL, the co-
presence of KRAS/NRAS/BRAF mutations and/or
NOTCH1 mutations and/or BIRC3 mutations along with a
UM IGHV gene status and over-expression of surface
receptors mediating microenvironment interactions (e.g.,
CD49d) more likely characterizes CLL with ampliﬁed
pro-survival and proliferative signals [8, 9, 15]. This may
explain the clinical association between KRAS/NRAS
mutations and shorter TFS, as shown in the present
analysis.
Given the reported high risk of poor response and
development of chemo-resistance characterizing CLL cases
with KRAS/NRAS mutations [4–6], additional therapeutic
strategies should be considered for the treatment of these
cases, including MEK/ERK inhibitors, employed alone or
in combination with conventional therapies.
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Table 1 Cox regression analysis
of treatment-free survival in the
whole cohort
Univariable Multivariable (n= 365)
N pts
analyzed
HR (95% CI) p-value HR (95% CI) p-value
male gender 442 0.97 (0.76–1.22) 0.8 − −
age ≥ 65 441 0.97 (0.77–1.23) 0.8 − −
Rai stage II–III–IV 434 2.60 (2.03–3.32) <0.0001 2.59 (1.98–3.41) <0.0001
CD49d positive (≥30%) 440 1.48 (1.13–1.92) 0.004 1.65 (1.22–2.23) 0.001
CD38 positive (≥30%) 439 1.13 (0.89–1.43) 0.3 − −
ZAP-70 positive (≥20%) 389 1.44 (1.11–1.87) 0.005 n.i. n.i.
IGHV unmutated 428 2.16 (1.66–2.8) <0.0001 1.83 (1.37–2.45) <0.0001
TP53 disrupted (del17p and/or
TP53 mutated)
442 1.70 (1.24–2.32) 0.0008 1.46 (1.05–2.03) 0.024
NOTCH1 mutated 442 1.37 (1.08–1.73) 0.009 n.i. n.i.
SF3B1 mutated 327 1.46 (0.90–2.38) 0.1 − −
BIRC3 mutated 343 0.93 (0.65–1.34) 0.7 − −
KRAS mutated 442 1.49 (0.96–2.30) 0.073 − −
NRAS mutated 442 1.86 (0.99–3.50) 0.055 − −
BRAF mutated 442 1.34 (0.75–2.40) 0.3 − −
KRAS/NRAS mutated 442 1.54 (1.05–2.25) 0.025 1.56 (1.04–2.36) 0.033
Factors with p-value <0.05 in univariable analysis were entered in the multivariable analysis
HR hazard ratio, CI conﬁdence interval, n.i. variables not included in the model after stepwise selection
2114 Letter
of Molecular Oncology, Department of Translational Research, CRO
Aviano, Italy) for helpful discussion.
Compliance with ethical standards
Conﬂict of interest The authors declare that they have no conﬂict of
interest.
Publisher’s note: Springer Nature remains neutral with regard to
jurisdictional claims in published maps and institutional afﬁliations.
Open Access This article is licensed under a Creative Commons
Attribution 4.0 International License, which permits use, sharing,
adaptation, distribution and reproduction in any medium or format, as
long as you give appropriate credit to the original author(s) and the
source, provide a link to the Creative Commons license, and indicate if
changes were made. The images or other third party material in this
article are included in the article’s Creative Commons license, unless
indicated otherwise in a credit line to the material. If material is not
included in the article’s Creative Commons license and your intended
use is not permitted by statutory regulation or exceeds the permitted
use, you will need to obtain permission directly from the copyright
holder. To view a copy of this license, visit http://creativecommons.
org/licenses/by/4.0/.
References
1. Simanshu DK, Nissley DV, McCormick F. RAS proteins and their
regulators in human disease. Cell. 2017;170:17–33.
2. Landau DA, Tausch E, Taylor-Weiner AN, Stewart C, Reiter JG,
Bahlo J, et al. Mutations driving CLL and their evolution in
progression and relapse. Nature. 2015;526:525–30.
3. Puente XS, Bea S, Valdes-Mas R, Villamor N, Gutierrez-Abril J,
Martin-Subero JI, et al. Non-coding recurrent mutations in chronic
lymphocytic leukaemia. Nature. 2015;526:519–24.
4. Herling CD, Abedpour N, Weiss J, Schmitt A, Jachimowicz RD,
Merkel O, et al. Clonal dynamics towards the development of
venetoclax resistance in chronic lymphocytic leukemia. Nat
Commun. 2018;9:727.
5. Pandzic T, Larsson J, He L, Kundu S, Ban K, Akhtar-Ali M, et al.
Transposon mutagenesis reveals ﬂudarabine resistance
mechanisms in chronic lymphocytic leukemia. Clin Cancer Res.
2016;22:6217–27.
6. Takahashi K, Hu B, Wang F, Yan Y, Kim E, Vitale C, et al.
Clinical implications of cancer gene mutations in patients with
chronic lymphocytic leukemia treated with lenalidomide. Blood.
2018;131:1820–32.
7. Gimenez N, Martinez-Trillos A, Montraveta A, Lopez-Guerra
M, Rosich L, Nadeu F, et al. Mutations in RAS-BRAF-MAPK-
ERK pathway deﬁne a speciﬁc subgroup of patients with
adverse clinical features and provide new therapeutic options in
chronic lymphocytic leukemia. Haematologica. 2018;104:
576–86.
8. Bulian P, Bomben R, Bo MD, Zucchetto A, Rossi FM, Degan M,
et al. Mutational status of IGHV is the most reliable prognostic
marker in trisomy 12 chronic lymphocytic leukemia. Haemato-
logica. 2017;102:e443–e446.
9. Zucchetto A, Caldana C, Benedetti D, Tissino E, Rossi FM,
Hutterer E, et al. CD49d is overexpressed by trisomy 12 chronic
lymphocytic leukemia cells: evidence for a methylation-dependent
regulation mechanism. Blood. 2013;122:3317–21.
10. Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero
G, Dohner H, et al. iwCLL guidelines for diagnosis, indications
for treatment, response assessment, and supportive management
of CLL. Blood. 2018;131:2745–60.
11. Yaktapour N, Meiss F, Mastroianni J, Zenz T, Andrlova H,
Mathew NR, et al. BRAF inhibitor-associated ERK activation
drives development of chronic lymphocytic leukemia. J Clin
Invest. 2014;124:5074–84.
12. Nadeu F, Clot G, Delgado J, Martin-Garcia D, Baumann T, Sal-
averria I, et al. Clinical impact of the subclonal architecture and
mutational complexity in chronic lymphocytic leukemia. Leuke-
mia. 2018;32:645–53.
13. Grabocka E, Bar-Sagi D. Mutant KRAS enhances tumor cell ﬁt-
ness by upregulating stress granules. Cell. 2016;167:1803–13.
14. Cimmino A, Calin GA, Fabbri M, Iorio MV, Ferracin M, Shimizu
M, et al. miR-15 and miR-16 induce apoptosis by targeting BCL2.
Proc Natl Acad Sci USA. 2005;102:13944–9.
15. Benedetti D, Tissino E, Pozzo F, Bittolo T, Caldana C, Perini C,
et al. NOTCH1 mutations are associated with high CD49d
expression in chronic lymphocytic leukemia: link between the
NOTCH1 and the NF-kappaB pathways. Leukemia. 2018;32:
654–62.
Letter 2115
